ImmuneOnco Biopharmaceuticals (Shanghai) Balance Sheet Health
Financial Health criteria checks 5/6
ImmuneOnco Biopharmaceuticals (Shanghai) has a total shareholder equity of CN¥748.3M and total debt of CN¥60.0M, which brings its debt-to-equity ratio to 8%. Its total assets and total liabilities are CN¥874.6M and CN¥126.3M respectively.
Key information
8.0%
Debt to equity ratio
CN¥59.98m
Debt
Interest coverage ratio | n/a |
Cash | CN¥608.56m |
Equity | CN¥748.29m |
Total liabilities | CN¥126.30m |
Total assets | CN¥874.59m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 1541's short term assets (CN¥686.7M) exceed its short term liabilities (CN¥115.9M).
Long Term Liabilities: 1541's short term assets (CN¥686.7M) exceed its long term liabilities (CN¥10.4M).
Debt to Equity History and Analysis
Debt Level: 1541 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 1541's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1541 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 1541 has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 21.8% each year.